Inhibitory effect of troleandomycin on the metabolism of omeprazole is CYP2C19 genotype-dependent

References

• ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A. and BIRKETT, D. J., 1993, Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. British Journal of Clinical Pharmacology, 36, 521–530.
   PubMed Web of Science ®Google Scholar
• ANDERSSON, T., MINERS, J. O., VERONSES, M. E. and BIRKETT, D. J., 1994, Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. British Journal of Clinical Pharmacology, 37, 597–604.
   PubMed Web of Science ®Google Scholar
• ANDERSSON, T., REGARDH, C. G., DAHL-PUUSTINEN, M. L. and BERTILSSON, L., 1990, Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Therapy and Drug Monitoring, 12, 415–416.
   Google Scholar
• ANDERSSON, T., REGÀRDH, C. G., Lou, Y. C., ZHANG, Y., DAHL, M. L. and BERTILSSON, L., 1992, Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics, 2, 25–31.
   Google Scholar
• BALIAN, J. D., SUKHOVA, N., HARRIS, J. W., HEWETT, J., PICKLE, L., GOLDSTEIN, J. A., WOOSLEY, R. L. and FLOCKHART, D. A., 1995, The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clinical Pharmacology and Therapeutics, 57, 662–669.
   PubMed Web of Science ®Google Scholar
• BöTTIGER, Y., TYBRING, G., GöTHARSON, E. and BERTILSSON, L., 1997, Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin. Clinical Pharmacology and Therapeutics, 62, 384–391.
   PubMed Web of Science ®Google Scholar
• CEDERBORG, C., ANDERSSON, T. and SKANBERG, I., 1989, Omeprazole: pharmacokinetics and metabolism in man. Scandinavian Journal of Gastroenterology, 24\(suppl. 166), 33–40.
   PubMed Web of Science ®Google Scholar
• CHANG, T. H., GONZALEZ, F. J. and WAXMAN, D. J., 1994, Evaluation of triacetyloleandomycin, (-naphthofiarone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Archives of Biochemistry and Biophysics, 311, 437–442.
   PubMed Web of Science ®Google Scholar
• CHIBA, K., KOBAYASHI, K., MANABE, K., TANI, M., KAMOTAKI, T. and ISHIZAKI, T., 1993, Oxidative metabolism of omeprazole in human liver microsomes: co-segregation with S-mephenytoin 4-hydroxylation. Journal of Pharmacology and Experimental Therapeutics, 266, 52–59.
   PubMed Web of Science ®Google Scholar
• CURI-PEDROSA, R., PICHARD, L., BONFILS, C., JACOZ-AIGRAIN, E. and MAUREL, P., 1993, Major implication of cytochrome P4503A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes. British Journal of Clinical Pharmacology, 36, 156.
   Google Scholar
• DE MORAIS, S. M. F., GOLDSTEIN, J. A., XIE, H. G., HUANG, S. L., Lu, Y. Q., XIA, H., XIAO, Z. S., HE, N. and ZHou, H. H., 1995, Genetic analysis of the S-mephenytoin polymorphism in Chinese population. Clinical Pharmacology and Therapeutics, 58, 404–411.
   Google Scholar
• DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., MEYER, U. S., NAKAMURA, K. and GOLDSTEIN, J. A., 1994a, Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin in Japanese. Molecular Pharmacology, 46, 594–598.
   Google Scholar
• DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., NAKAMURA, K., MEYER, U. S. and GOLDSTEIN, J. A., 1994b, The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. Journal of Biological Chemistry, 269, 15419–15422.
   Google Scholar
• GOLDSTEIN, J. A., 2001, Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. British Journal of Clinical Pharmacology, 52, 349–355.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN, J. A., FALETTO, M. B., ROMKES-SPARKS, M., SULLIVAN, T., KITAREEWAN, S., RAUCY, J. L., LASKER, J. M. and GHANAYEM, B. I., 1994, Evidence that 2C19 is the major S-mephenytoin 4'-hydroxylase in humans. Biochemistry, 3, 1743–1752.
   Google Scholar
• IBEANU, G. C., BLAISDELL, J., FERGUSON, R. J., GHANAYEM, B. I., BROSEN, K., BENHAMOU, S., BOUCHARDY, C., WILKINSON, G. R., DAYER, P. and GOLDSTEIN, J. A., 1999, A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. Journal of Pharmacology and Experimental Therapeutics, 290, 635–640.
   PubMed Web of Science ®Google Scholar
• IBEANU, G. C., GOLDSTEIN, J. A., MEYER, U., BENHAMOU, S., BOUCHARDY, C., DAYER, P., GHANAYEM, B. I. and BLAISDELL, J., 1998, Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. Journal of Pharmacology and Experimental Therapeutics, 286,1490–1495.
   PubMed Web of Science ®Google Scholar
• IEIRI, I., KUBOTA, T., URAE, A., KIMURA, M., WADA, Y., MAMIYA, K., YOSHIOKA, S., IRIE, S., AMAMOTO, T., NAKAMURA, K., NAKANO, S. and HIGUCHI, S., 1996, Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19„,2 in exon 4, in Japanese subjects. Clinical Pharmacology and Therapeutics, 59, 647–653.
   PubMed Web of Science ®Google Scholar
• KIMURA, M., IEIRI, I., WADA, Y., MAMIYA, K., URAE, A., Iimom, E., SAKI, T., OTSUBO, K. and HIGUCHI, S., 1998, Reliability of the omeprazole hydroxylation index for CYP2C19 phenotyping: possible effect of age, liver disease and length of therapy. British Journal of Clinical Pharmacology, 47, 115–119.
   Web of Science ®Google Scholar
• KINIRONS, M. T., O'SHEA, D., DOWNING, T. E., FITZWILLIAM, A. T., JOELLENBECK, L., GROOPMAN, J. D., WILKINSON, G. R. and WOOD, A. J., 1993, Absence of correlations among three putative in vivo probes of human cytochrome P450 3A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621–629.
   Google Scholar
• LINDBERG, P., NORDBERG, P., ALMINGER, T., BRANDSTROM, A. and WALLMARK, B., 1986, The mechanism of action of the gastric acid secretion inhibitor omeprazole. Journal of Medical Chemistry, 29, 1327–1329.
   PubMed Web of Science ®Google Scholar
• PESSAYRE, D., KONSTANTINOVA-MITCHEVA, M., DESCATOIRE, V., COBERT, B., WANDSCHEER, J. C., LEVEL, R., FELDMANN, G., MANSUY, D. and BENHAMOU, J. P., 1981, Hypoactivity of cytochrome P-450 after triacetyloleandomycin administration. Biochemical Pharmacology, 30, 559–564.
   Google Scholar
• REGARDH, C. G., 1986, Pharmacokinetics and metabolism of omeprazole in man. Scandinavian Journal of Gastroenterology, 21\(suppl. 118), 99–104.
   Web of Science ®Google Scholar
• SAMBROOK, J., FRITSCH, E. F. and MANIATIS, T., 1989, Molecular Cloning: A Laboratory Manual, 2nd edn (Cold Spring Harbor: Cold Spring Harbor Laboratory), pp. 16–19.
   Google Scholar
• SHU, Y., WANG, L. S., Xu, Z. H., HE, N., XIAO, W. M., WANG, W., HUANG, S. L. and ZHOU, H. H., 2000, 5-Hydroxylation of omeprazole by human liver microsomal fractions from Chinese population related to CYP2C19 gene dose and individual ethnicity. Journal of Pharmacology and Experimental Therapeutics, 295, 844–851.
   PubMed Web of Science ®Google Scholar
• SOHN, D. R., KOBAYASHI, K., CHIBA, K., LEE, K. H., SHIN, S. G. and ISHIZAKI, T., 1992, Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4-hydroxylaiton recruited from an oriental population. Journal of Pharmacology and Experimental Therapeutics, 262, 1195–1202.
   PubMed Web of Science ®Google Scholar
• WATKINS, P. B., TURGEON, D. K., SAENGER, P., LOWN, K. S., KOLARS, J. C., HAMILTON, T., FISHMAN, K., GUZELIAN, P. S. and VOORHEES, J. J., 1992, Comparison of urinary 613-cortisol and the erythromycin breath test as measures of hepatic P450 IIIA(CYP3A) activity. Clinical Pharmacology and Therapeutics, 52, 265–273.
   PubMed Web of Science ®Google Scholar
• WILKINSON, G. R., GUENGERICH, F. P. and BRANCH, R. A., 1989, Genetic polymorphism of S-mephenytoin 4'-hydroxylation. Pharmacology and Therapy, 43, 53–76.
   PubMed Web of Science ®Google Scholar
• WILLIAMS, M. L., BHARGAVA, P., CHERROUK, I., MARSHALL, J. L., FLOCKHART, D. A. and WAINER, I. W., 2000, A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. British Journal of Clinical Pharmacology, 49, 485–488.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VANDENBRANDEN, M., 1993, Isolation and characterization of human liver cytochrome CYP2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Archives of Biochemistry and Biophysics, 306, 240–245.
   PubMed Web of Science ®Google Scholar
• XIAO, Z. S., GOLDSTEIN, J. A., XIE, H. G., BLAISDELL, J., WANG, W., JIANG, C. H., YAN, F. X., HE, N., HUANG, S. L., Xu, Z. H. and Zilou, H. H., 1997, Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. Journal of Pharmacology and Experimental Therapeutics, 281, 604–609.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI, H., INouE, K., SHAW, P. M., CHECOVICH, W. J., GUENGERICH, P. and SHIMADA, T., 1997, Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. Journal of Pharmacology and Experimental Therapeutics, 283, 434–442.
   PubMed Web of Science ®Google Scholar